Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

被引：2
|
作者：
Regidor, Bernard Sean [1 ]
Siddiqi, Dilawer [1 ]
Beatty, Bethany Marie [1 ]
Goldwater, Marissa-Skye [2 ]
Jew, Scott [1 ,2 ]
Bujarski, Sean [1 ,2 ]
Swift, Regina [1 ]
Kim, Susanna
Berenson, James R. R. [1 ,2 ,3 ,4 ]
机构：
[1] Berenson Canc Ctr, West Hollywood, CA USA
[2] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[3] Oncotherapeut, West Hollywood, CA USA
[4] Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, West Hollywood, CA 90069 USA
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2023年 / 110卷 / 02期
关键词：
anti-CD38; daratumumab; multiple myeloma; venetoclax;
D O I：
10.1111/ejh.13896
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 37 条
  • [1] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
    Richardson, P.
    Lokhorst, H.
    Palumbo, A.
    Nahi, H.
    Laubach, J.
    Gimsing, P.
    Lisby, S.
    Cakana, A.
    Brun, N. Constantin
    Plesner, T.
    DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
  • [2] Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab
    Yashar, David
    Regidor, Bernard Sean S.
    Jew, Scott Kristian
    Bujarski, Sean
    Goldwater, Marissa-Skye
    Swift, Regina
    Schwartz, Gary Edward
    Eshaghian, Shahrooz
    Vescio, Robert
    Berenson, James R.
    BLOOD, 2021, 138 : 3785 - +
  • [3] Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma
    Hong, Augustine
    Eduafo, Augusta
    Schmikla, Hannah
    Brown, George
    Ravi, Gayathri
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2020, 136
  • [4] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
    Pimentel, Villar M. A.
    Anguita, Arance M. M.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
  • [5] Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
    Donald C. Moore
    Joseph B. Elmes
    Justin R. Arnall
    Scott A. Strassels
    Jai N. Patel
    International Journal of Clinical Pharmacy, 2023, 45 : 1492 - 1495
  • [6] Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
    Moore, Donald C. C.
    Elmes, Joseph B. B.
    Arnall, Justin R. R.
    Strassels, Scott A. A.
    Patel, Jai N. N.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (06) : 1492 - 1495
  • [7] Anti-CD38 monoclonal antibody impairs CD34+mobilization and affects clonogenic potential in multiple myeloma patients
    Zappaterra, Arianna
    Civettini, Ivan
    Cafro, Anna Maria
    Pezzetti, Laura
    Pierini, Silvia
    Anghilieri, Michela
    Bellio, Laura
    Bertazzoni, Paola
    Grillo, Giovanni
    Minga, Periana
    Pioltelli, Maria L.
    Ravano, Emanuele
    Sassone, Marianna
    V. Vigano, Clara
    Volpato, Elisabetta B.
    Gambacorti-Passerini, Carlo
    Rossini, Silvano
    Cairoli, Roberto
    Crocchiolo, Roberto
    BLOOD TRANSFUSION, 2024, 22 (04) : 328 - 337
  • [8] Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
    Quach, Hang
    Benson, Simon
    Haysom, Helen
    Wilkes, Anne-Marie
    Zacher, Nicole
    Cole-Sinclair, Merrole
    Prince, Henry Miles
    Mollee, Peter
    Spencer, Andrew
    Ho, Phoebe Joy
    Harrison, Simon J.
    Lee, Cindy
    Augustson, Bradley
    Daly, James
    INTERNAL MEDICINE JOURNAL, 2018, 48 (02) : 210 - 220
  • [9] Survival and drug treatment patterns in multiple myeloma patients exposed to an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory imide drugs
    Hoveling, Liza
    de Jong, Hilda J.
    Penning-van Beest, Fernie J.
    Holthuis, Emily
    Smits, Elisabeth
    Dalhuisen, Sander
    Dinkla, Sip
    Herings, Ron M. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 313 - 314
  • [10] Treatment patterns and clinical outcomes in multiple myeloma patients previously treated with lenalidomide and an anti-CD38 monoclonal antibody: findings from the PREAMBLE registry
    Goldschmidt, Hartmut
    Vij, Ravi
    Kuter, David
    Cella, David
    Moreau, Philippe
    Durie, Brian
    Petrucci, Maria-Teresa
    Tang, Yuexin
    Dhanasiri, Sujith
    Gu, Jin
    Fish, Susan
    Ramasamy, Karthik
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S180 - S181
1234